Skip to main content

Table 1 Laboratory findings on admission (July 2016)

From: Acute hypopituitarism associated with periorbital swelling and cardiac dysfunction in a patient with pituitary tumor apoplexy: a case report

Hematology

 Red blood cells

363 Ă— 104/μL

(435–555)

 Hemoglobin

10.5 g/dL

(13.7–16.8)

 Hematocrit

32.3%

(40.7–50.1)

 White blood cells

4100/μL

(3300–8600)

 Platelets

18.7 Ă— 104/μL

(15.8–34.8)

Blood chemistry

 Total protein

6.5 g/dL

(6.6–8.1)

 Albumin

3.7 g/dL

(4.1–5.1)

 Aspartate aminotransferase

19 IU/L

(13–33)

 Alanine aminotransferase

15 IU/L

(10–42)

 Creatine kinase

57 IU/L

(45–163)

 Urea nitrogen

16.3 mg/dL

(8.0–18.4)

 Creatinine

1.01 mg/dL

(0.65–1.07)

 Sodium

138 mmol/L

(138–145)

 Potassium

3.9 mmol/L

(3.6–4.8)

 Chloride

103 mmol/L

(101–108)

 C-reactive protein

5.53 mg/dL

(<0.14)

 Prothrombin time

105.8 seconds

(70–130)

 APTT

27.9 seconds

(24–32)

 Fibrinogen

278.1 mg/dL

(200–400)

 Casual plasma glucose

106 mg/dL

(70–139)

 Glycated hemoglobin

4.9%

(4.6–6.2)

 Brain natriuretic peptide

421.6 pg/mL

(<18.4)

 Plasma osmolality

281 mOsm/L

(275–290)

 Plasma arginine vasopressin

2.3 pg/mL

 

 Prolactin

28.5 ng/mL

(3.6–12.8)

 Thyroid-stimulating hormone

0.03 μIU/mL

(0.50–5.00)

 Free triiodothyronine

3.73 pg/mL

(2.30–4.00)

 Free thyroxine

0.98 ng/dL

(0.90–1.70)

 Adrenocorticotropic hormone

16.3 pg/mL

(7.2–63.3)

 Cortisol

1.8 μg/dL

(4.5–21.1)

 Dehydroepiandrosterone sulfate

138 ng/mL

(50– 2,530)

 Aldosterone

6.2 ng/dL

(3.0–15.9)

 Plasma renin activity

0.2 ng/mL/h

(0.2–2.3)

 Noradrenaline

0.70 ng/mL

(0.10–0.50)

 Adrenaline

0.06 ng/mL

(0–0.10)

 Dopamine

0.01 ng/mL

(0–0.03)

Urinalysis

 Specific gravity

1.024

(1.005–1.020)

 pH

5.5

(5.5–7.5)

 Glucose

Negative

 

 Protein

Negative

 

 Occult blood

Negative

 

 Inflammatory cells

Negative

 
  1. The reference range for each parameter is shown in parentheses
  2. Blood samples were taken with the patient in the supine position at 9 AM of the day of admission. The patient underwent thyroid hormone replacement therapy with oral levothyroxine (100 μg/day)
  3. APTT activated partial thromboplastin time